Guidelines for Managing Hyperlipidemia
Risk Assessment and Treatment Approach
- The European Society of Cardiology recommends evaluating total cardiovascular risk before initiating treatment, considering factors such as age, family history, hypertension, diabetes, and existing cardiovascular disease 1
- The European Society of Cardiology suggests obtaining a complete lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides) for risk assessment 1
- The Kidney International guidelines assess ASCVD risk based on LDL-C, Apo B, triglyceride and Lp(a) levels, age group, and ASCVD 'risk enhancers' 2, 3
- Risk enhancers include chronic inflammatory conditions, history of preeclampsia, early menopause, South Asian ancestry, chronic kidney disease, and HIV/AIDS, as stated by the Kidney International guidelines 3
Lifestyle Modifications
- The Kidney International guidelines recommend implementing lifestyle modifications in all patients as first-line therapy and as synergistic means for improving lipid control 2
- The Kidney International guidelines suggest restricting dietary sodium to <2.0 g/day (<90 mmol/day) 2
- The Kidney International guidelines recommend considering a plant-based diet and avoiding red meat 3
- The European Heart Journal guidelines suggest consuming foods rich in omega-3 polyunsaturated fats (fish, nuts, flaxseed oil) 4
- The European Heart Journal guidelines recommend considering foods enriched with phytosterols (1-2 g/day) for individuals with elevated total and LDL cholesterol 4
Pharmacological Therapy
Statins
- The Kidney International guidelines recommend starting with statins as first-line therapy for persistent hyperlipidemia 2, 3
- The Kidney International guidelines suggest aligning statin dosage intensity to ASCVD risk 3
- The European Heart Journal guidelines recommend monitoring lipid levels 4-12 weeks after starting treatment or dose adjustment 5
- The European Heart Journal guidelines suggest monitoring for common side effects, including myopathy and elevated liver enzymes 5
Non-Statin Therapies
- The Kidney International guidelines recommend considering initiation of non-statin therapy in those who cannot tolerate statins or are at high ASCVD risk and fail to achieve LDL-C or triglyceride goals despite maximally tolerated statin dose 3
- The Kidney International guidelines suggest options, including bile acid sequestrants, fibrates, ezetimibe, PCSK9 inhibitors, and nicotinic acid, with caution in certain populations 3, 6
Special Populations
Patients with HIV on Antiretroviral Therapy
- The Clinical Infectious Diseases guidelines recommend pravastatin (20-40 mg daily) or atorvastatin (10 mg daily) for elevated LDL-C 6, 7
- The Clinical Infectious Diseases guidelines suggest gemfibrozil (600 mg twice daily) or micronized fenofibrate (54-160 mg daily) for severe hypertriglyceridemia (>500 mg/dL) 6, 7
Pediatric Patients
- The Kidney International guidelines recommend considering statins in children aged >8 years with concerning family history or extremely elevated LDL-C or Lp(a) 2, 3
- The Kidney International guidelines suggest lifestyle modifications as first-line treatment for hyperlipidemia in children 3
Monitoring
- The European Heart Journal guidelines recommend checking lipid levels 8 (±4) weeks after starting treatment or adjusting dose 5
- The European Heart Journal guidelines suggest monitoring liver enzymes (ALT) before treatment and 8-12 weeks after starting therapy or dose increase 5
- The European Heart Journal guidelines recommend checking creatine kinase (CK) before starting therapy and being alert for myopathy symptoms, especially in high-risk patients 5